325 related articles for article (PubMed ID: 25269954)
21. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI
Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321
[TBL] [Abstract][Full Text] [Related]
23. Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
Denorme M; Yon L; Roux C; Gonzalez BJ; Baudin E; Anouar Y; Dubessy C
Cancer Lett; 2014 Oct; 352(2):236-44. PubMed ID: 25016061
[TBL] [Abstract][Full Text] [Related]
24. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2.
Kernt M; Thiele S; Neubauer AS; Koenig S; Hirneiss C; Haritoglou C; Ulbig MW; Kampik A
Retina; 2012 Sep; 32(8):1652-63. PubMed ID: 22466477
[TBL] [Abstract][Full Text] [Related]
26. Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma.
Canter RJ; Ames E; Mac S; Grossenbacher SK; Chen M; Li CS; Borys D; Smith RC; Tellez J; Sayers TJ; Monjazeb AM; Murphy WJ
BMC Cancer; 2014 Oct; 14():756. PubMed ID: 25301268
[TBL] [Abstract][Full Text] [Related]
27. [Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Török S; Döme B
Magy Onkol; 2012 Mar; 56(1):3-15. PubMed ID: 22403757
[TBL] [Abstract][Full Text] [Related]
28. [Novelties in the treatment for advanced renal-cell cancer].
Maráz A
Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
[TBL] [Abstract][Full Text] [Related]
29. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Barbastefano J; Garcia JA; Elson P; Wood LS; Lane BR; Dreicer R; Campbell SC; Rini BI
BJU Int; 2010 Nov; 106(9):1266-9. PubMed ID: 20346042
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous Tumor.
Ebata T; Shimoi T; Bun S; Miyake M; Yoshida A; Shimomura A; Noguchi E; Yonemori K; Shimizu C; Fujiwara Y; Narita Y; Tamura K
Oncology; 2018; 94(6):340-344. PubMed ID: 29614488
[TBL] [Abstract][Full Text] [Related]
31. Species differences in ocular pharmacokinetics and pharmacological activities of regorafenib and pazopanib eye-drops among rats, rabbits and monkeys.
Horita S; Watanabe M; Katagiri M; Nakamura H; Haniuda H; Nakazato T; Kagawa Y
Pharmacol Res Perspect; 2019 Dec; 7(6):e00545. PubMed ID: 31763044
[TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
Rini BI
Cancer; 2009 May; 115(10 Suppl):2306-12. PubMed ID: 19402073
[TBL] [Abstract][Full Text] [Related]
33. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.
Stacchiotti S; Ferrari S; Redondo A; Hindi N; Palmerini E; Vaz Salgado MA; Frezza AM; Casali PG; Gutierrez A; Lopez-Pousa A; Grignani G; Italiano A; LeCesne A; Dumont S; Blay JY; Penel N; Bernabeu D; de Alava E; Karanian M; Morosi C; Brich S; Dagrada GP; Vallacchi V; Castelli C; Brenca M; Racanelli D; Maestro R; Collini P; Cruz J; Martin-Broto J
Lancet Oncol; 2019 Sep; 20(9):1252-1262. PubMed ID: 31331701
[TBL] [Abstract][Full Text] [Related]
34. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study.
Oh CR; Hong JY; Kim JH; Lee JS; Kim HS; Kim TW; Ahn JH; Kim JE
Target Oncol; 2020 Aug; 15(4):485-493. PubMed ID: 32607656
[TBL] [Abstract][Full Text] [Related]
35. Pazopanib efficacy in recurrent central nervous system hemangiopericytomas.
Apra C; Alentorn A; Mokhtari K; Kalamarides M; Sanson M
J Neurooncol; 2018 Sep; 139(2):369-372. PubMed ID: 29700673
[TBL] [Abstract][Full Text] [Related]
36. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
[TBL] [Abstract][Full Text] [Related]
37. Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.
Hess G; Borker R; Fonseca E
Clin Genitourin Cancer; 2013 Jun; 11(2):161-7. PubMed ID: 23267717
[TBL] [Abstract][Full Text] [Related]
38. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
[TBL] [Abstract][Full Text] [Related]
39. Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience.
Levard A; Derbel O; Méeus P; Ranchère D; Ray-Coquard I; Blay JY; Cassier PA
BMC Cancer; 2013 Mar; 13():109. PubMed ID: 23496996
[TBL] [Abstract][Full Text] [Related]
40. Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.
Domont J; Massard C; Lassau N; Armand JP; Le Cesne A; Soria JC
Invest New Drugs; 2010 Apr; 28(2):199-202. PubMed ID: 19352594
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
